PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
3 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
-
Citations
37 Claims
-
1. A compound of formula I:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
2. The compound of claim 1, wherein, independently for each occurrence:
-
R1 is H, C1-C6 alkyl, C3-C8 cycloalkyl, halo, CN, NR8SO2R8, SO2R8, SR8, SOR8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, heterocycloalkyl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8, or two R1 taken together form an oxo group, or a 3 to 7 membered fused cycloalkyl ring, or a 3 to 7 membered spirocyclic ring; R2 is H, C1-C6 alkyl, C1-C6 haloalkyl, CN, OH, SO2R8, SR8, SOR8, CO2R8, CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8; R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, CO2R8, CORS, COH, CON(R8)2, CF3, CH2CF3, CH2CHF2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8; R4 is H, C1-C6 alkyl, halo, C3-C8 cycloalkyl, wherein up to two CH2 units may be replaced by O, CO, S, SO, SO2, or NR8, or 2 R4 taken together form a fused 3 to 7 membered cycloalkyl ring; R8 is H, C1-C6 alkyl, CF3, C3-C8 cycloalkyl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR, or 2 R8 taken together with the atoms to which they are attached form a ring; R9 is H, CF3, CO2R, OH, aryl, heteroaryl, C3-C8 cycloalkyl, heterocycloalkyl, N(R)2, NRCOR, CON(R)2, CN, or SO2R; R is H, C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or heterocycloalkyl; A is an optionally substituted aryl, heteroaryl or heterocyclic; m is an integer from 0 to 4 inclusive; n is an integer from 0 to 3 inclusive; and o is an integer from 0 to 4 inclusive.
-
-
3. The compound of claim 1, wherein R1 is C1-C8 alkyl or two R1 taken together with the atoms to which they are attached form a 3 to 7 membered fused cycloalkyl or spirocyclic ring.
-
4. The compound of claim 1, wherein R1 is CH3 or two R1 taken together form a fused cyclohexyl ring.
-
5. The compound claim 1, wherein R2 is H, C1-C8 alkyl, halo, CF3, CN, COR8, CON(R8)2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8.
-
6. The compound of claim 1, wherein R2 is COCF3, COtBu, Cl, COCH3, CF2CF3, CH2CF3, CF3, CN, Br, COCH(CH3)2, COCH2CH3, CH(OH)CF3, SO2CH3,
-
7. The compound of claim 1, wherein R3 is H, C1-C8 alkyl, CO2R8, COR8, COH, CON(R8)2 or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8.
-
8. The compound of claim 1, wherein R3 is H, CH3, CH2CH3, CH2CH2OCH3, CH2CH2OH, CH2CO2CH2CH3, CH2CON(CH3)2, CH2CONH2, CH2CN, benzyl, cyclobutyl, CH2CH(CH2)2, CH(CH2)2, CH2CF3, CH2CHF2, COCH3, COCH2CH3, CO2CH3, CO2CH2CH3, COH, CONH(CH3)2, or CONHCH3.
-
9. The compound of claim 1, wherein R4 is H, halo, or C1-C8 alkyl.
-
10. The compound of claim 1, wherein R4 is H, F, or CH3.
-
11. The compound of claim 1, wherein m is 0, 1, or 2.
-
12. The compound of claim 1, wherein n is 0, 1, or 2.
-
13. The compound of claim 1, wherein o is 0 or 1.
-
14. The compound of claim 1, wherein A is
-
15. The compound of claim 14, wherein R5 is H, C1-C8 alkyl, C1-C8 alkoxy, halo, OCF3, OCHF2, R9, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR7.
-
16. The compound of claim 14, wherein R5 is H, CH3, OCH3, OCF3, OPh, Ph, OCHF2, or F.
-
17. The compound of claim 14, wherein R6 is H, C1-C8 alkyl, C1-C8 alkoxy, halo, R9, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8.
-
18. The compound of claim 14, wherein R6 is H, CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CF3, CN, Ph, SO2CH3, OH, CH(CH3)2, OCH2CH2CH2CH3, F, Cl, or CH2OH.
-
19. The compound of claim 14, wherein R7 is H, C1-C8 alkyl, C1-C8 alkoxy, SO2R8, OSO2R8, SO2N(R8)2, R9, OCHF2, OCF3, or a straight chain, branched, or cyclic (C1-C8)-(R9)p, wherein p is 1 or 2 and wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8.
-
20. The compound of claim 14, wherein R7 is H, CH3, CH2CH3, tBu, Cl, F, OH, C(═
- CH2)CH3, OC(═
CH2)CH3, OCH3, OCH2CH2CH2CH3, CH2OH, OCH2CH2OH, OCH2CH2CH2OH, OtBu, OCH(CH3)(CH2CH3), OCH2C(CH3)2OH, C(CH3)2OH, CH2C(CH3)2OH, CH(OH)CH(CH3)2, C(CH3)2CH2OH, OCH2CH2CH(CH3)2, OCH2CH2CH3, OCH(CH3)2, OCH2CH2OCH3,
- CH2)CH3, OC(═
-
21. The compound of claim 14, wherein
-
22. The compound of claim 1, wherein A is heteroaryl or heterocyclic.
-
23. The compound of claim 22, wherein A is a monocyclic heteroaryl comprising 1 to 3 heteroatoms independently selected from N, O, or S.
-
24. The compound of claim 22, wherein A is selected from a bicyclic heteroaryl comprising from 1 to 3 heteroatoms independently selected from N, O, or S.
-
25. The compound of claim 22, wherein A is:
-
26. The compound of claim 1, wherein the compound has formula IA:
-
27. The compound of claim 26, wherein R2 is H, COCF3, COtBu, Cl, COCH3, CF2CF3, CH2CF3, CF3, CN, Br, COCH(CH3)2, COCH2CH3, CH(OH)CF3, SO2CH3,
-
28. The compound of claim 26, wherein R3 is H, CH3, CH2CH3, CH2CH2OCH3, CH2CH2OH, CH2CO2CH2CH3, CH2CON(CH3)2, CH2CONH2, CH2CN, benzyl, cyclobutyl, CH2CH(CH2)2, CH(CH2)2, CH2CF3, CH2CHF2, COCH3, COCH2CH3, CO2CH3, CO2CH2CH3, COH, CONH(CH3)2, or CONHCH3.
-
29. The compound of claim 26, wherein R6 is H, CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CF3, CN, Ph, SO2CH3, OH, CH(CH3)2, OCH2CH2CH2CH3, F, Cl, or CH2OH.
-
30. The compound of claim 26, wherein R7 is H, CH3, CH2CH3, tBu, Cl, F, OH, C(═
- CH2)CH3, OC(═
CH2)CH3, OCH3, OCH2CH2CH2CH3, CH2OH, OCH2CH2OH, OCH2CH2CH2OH, OtBu, OCH(CH3)(CH2CH3), OCH2C(CH3)2OH, C(CH3)2OH, CH2C(CH3)2OH, CH(OH)CH(CH3)2, C(CH3)2CH2OH, OCH2CH2CH(CH3)2, OCH2CH2CH3, OCH(CH3)2, OCH2CH2OCH3,
- CH2)CH3, OC(═
-
31. The compound of claim 26, wherein the
-
32. The compound of claim 1, wherein the compound is selected from the following table:
-
33. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
34. A method of inhibiting a voltage-gated sodium ion channel in:
-
a patient;
ora biological sample; comprising administering to the patient, or contacting the biological sample, with the compound of claim 1.
-
-
35. The method of claim 34, wherein the voltage-gated sodium ion channel is NaV 1.7.
-
36. A method of treating or lessening the severity in a subject of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpatic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress- or exercise induced angina, palpitations, hypertension, migraine, or abnormal gastro-intestinal motility, comprising administering an effective amount of a compound of claim 1.
-
37. The method of claim 36, wherein said method is used for treating or lessening the severity of femur cancer pain;
- non-malignant chronic bone pain;
rheumatoid arthritis;
osteoarthritis;
spinal stenosis;
neuropathic low back pain;
neuropathic low back pain;
myofascial pain syndrome;
fibromyalgia;
temporomandibular joint pain;
chronic visceral pain, abdominal pain;
pancreatic;
IBS pain;
chronic and acute headache pain;
migraine;
tension headache, including, cluster headaches;
chronic and acute neuropathic pain, post-herpatic neuralgia;
diabetic neuropathy;
HIV-associated neuropathy;
trigeminal neuralgia;
Charcot-Marie Tooth neuropathy;
hereditary sensory neuropathies;
peripheral nerve injury;
painful neuromas;
ectopic proximal and distal discharges;
radiculopathy;
chemotherapy induced neuropathic pain;
radiotherapy-induced neuropathic pain;
post-mastectomy pain;
central pain;
spinal cord injury pain;
post-stroke pain;
thalamic pain;
complex regional pain syndrome;
phantom pain;
intractable pain;
acute pain, acute post-operative pain;
acute musculoskeletal pain;
joint pain;
mechanical low back pain;
neck pain;
tendonitis;
injury/exercise pain;
acute visceral pain, abdominal pain;
pyelonephritis;
appendicitis;
cholecystitis;
intestinal obstruction;
hernias;
chest pain, cardiac pain;
pelvic pain, renal colic pain, acute obstetric pain, labor pain;
cesarean section pain;
acute inflammatory, burn and trauma pain;
acute intermittent pain, endometriosis;
acute herpes zoster pain;
sickle cell anemia;
acute pancreatitis;
breakthrough pain;
orofacial pain including sinusitis pain, dental pain;
multiple sclerosis (MS) pain;
pain in depression;
leprosy pain;
Behcet'"'"'s disease pain;
adiposis dolorosa;
phlebitic pain;
Guillain-Barre pain;
painful legs and moving toes;
Haglund syndrome;
erythromelalgia pain;
Fabry'"'"'s disease pain;
bladder and urogenital disease, including, urinary incontinence;
hyperactivity bladder;
painful bladder syndrome;
interstitial cyctitis (IC);
prostatitis;
complex regional pain syndrome (CRPS), type I and type II;
widespread pain, paroxysmal extreme pain, pruritis, tinnitis, or angina-induced pain.
- non-malignant chronic bone pain;
-
2. The compound of claim 1, wherein, independently for each occurrence:
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeVertex Pharmaceuticals Incorporated
-
Original AssigneeVertex Pharmaceuticals Incorporated
-
InventorsKallel, Edward Adam, Miller, Mark Thomas, Arumugam, Vijayalaksmi, McCartney, Jason, Anderson, Corey, Grootenhuis, Peter Diederik Jan, Hadida Ruah, Sara Sabina, Jiang, Licong
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/250
-
CPC Class CodesA61K 31/499 Spiro-condensed pyrazines o...A61K 31/506 not condensed and containin...A61P 1/00 Drugs for disorders of the ...A61P 1/02 Stomatological preparations...A61P 1/04 for ulcers, gastritis or re...A61P 1/18 for pancreatic disorders, e...A61P 11/02 Nasal agents, e.g. deconges...A61P 13/00 Drugs for disorders of the ...A61P 13/08 of the prostateA61P 13/10 of the bladderA61P 15/00 Drugs for genital or sexual...A61P 17/02 for treating wounds, ulcers...A61P 17/04 AntipruriticsA61P 19/02 for joint disorders, e.g. a...A61P 21/00 Drugs for disorders of the ...A61P 21/02 Muscle relaxants, e.g. for ...A61P 25/00 Drugs for disorders of the ...A61P 25/02 for peripheral neuropathiesA61P 25/04 Centrally acting analgesics...A61P 25/06 Antimigraine agentsA61P 25/08 : Antiepileptics; Anticonvuls...A61P 25/14 : for treating abnormal movem...A61P 25/18 : Antipsychotics, i.e. neurol...A61P 25/22 : AnxiolyticsA61P 25/24 : AntidepressantsA61P 25/28 : for treating neurodegenerat...A61P 27/16 : OtologicalsA61P 29/00 : Non-central analgesic, anti...A61P 43/00 : Drugs for specific purposes...A61P 5/00 : Drugs for disorders of the ...A61P 7/06 : AntianaemicsA61P 9/00 : Drugs for disorders of the ...A61P 9/06 : AntiarrhythmicsA61P 9/10 : for treating ischaemic or a...A61P 9/12 : AntihypertensivesC07D 471/20 : Spiro-condensed systemsC07D 519/00 : Heterocyclic compounds cont...